NasdaqCM - Delayed Quote USD
Dianthus Therapeutics, Inc. (DNTH)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 4:20 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 10 | 10 |
| Avg. Estimate | -0.59 | -0.65 | -2.21 | -2.76 |
| Low Estimate | -0.73 | -0.78 | -2.58 | -3.36 |
| High Estimate | -0.5 | -0.49 | -1.79 | -2.31 |
| Year Ago EPS | -3.78 | -0.71 | -8.45 | -2.21 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 8 | 8 |
| Avg. Estimate | 650k | 650k | 4.02M | 2.76M |
| Low Estimate | -- | -- | 2.7M | -- |
| High Estimate | 1.86M | 1.86M | 6.46M | 7.45M |
| Year Ago Sales | 924k | 457k | 2.83M | 4.02M |
| Sales Growth (year/est) | -29.70% | 42.20% | 42.30% | -31.30% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.56 | -1.01 | -0.44 | -0.55 |
| EPS Actual | -3.78 | -0.71 | -0.54 | -0.51 |
| Difference | -3.22 | 0.3 | -0.1 | 0.04 |
| Surprise % | -575.00% | 29.70% | -22.70% | 7.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.59 | -0.65 | -2.21 | -2.76 |
| 7 Days Ago | -0.59 | -0.65 | -2.21 | -2.76 |
| 30 Days Ago | -0.61 | -0.67 | -2.23 | -2.75 |
| 60 Days Ago | -0.61 | -0.67 | -2.29 | -2.8 |
| 90 Days Ago | -0.59 | -0.65 | -2.2 | -2.64 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | DNTH | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 84.40% | -- | -- | 3.70% |
| Next Qtr. | 8.50% | -- | -- | 7.90% |
| Current Year | 73.80% | -- | -- | 2.50% |
| Next Year | -24.90% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.88% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Initiated | Oppenheimer: Outperform | 10/3/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/26/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/12/2024 |
| Maintains | Wedbush: Outperform to Outperform | 8/9/2024 |
| Initiated | Baird: Outperform | 7/26/2024 |
| Initiated | Cantor Fitzgerald: Overweight | 6/27/2024 |
Related Tickers
SYRE Spyre Therapeutics, Inc.
32.76
0.00%
ELVN Enliven Therapeutics, Inc.
29.00
+3.50%
MLYS Mineralys Therapeutics, Inc.
14.40
+3.75%
COGT Cogent Biosciences, Inc.
11.90
+2.23%
TRML Tourmaline Bio, Inc.
28.26
-2.99%
ATXS Astria Therapeutics, Inc.
11.46
-2.55%
KROS Keros Therapeutics, Inc.
61.25
+0.26%
NGNE Neurogene Inc.
54.40
+2.80%
APGE Apogee Therapeutics, Inc.
53.53
-4.80%
ORKA Oruka Therapeutics, Inc.
29.76
+3.30%